VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                           

 

20th October 2014 - New research

CLINICAL TRIAL RESULTS OF DUAL LAYER L-DOPA

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

Dual layer L-dopa (IPX066), which is being developed for the treatment of Parkinson's Disease, unusually and advantageously combines the immediate release version of L-dopa with the controlled release version of L-dopa. An application by Impax is with the FDA for the marketing of IPX066 as Rytary. For more information go to Rytary 
                                                                                                                                                                                 The effect of Dual Layer L-dopa on Parkinson's Disease was compared to the effect of Sinemet plus Entacapone, which is one of the most effective formats of L-dopa. IPX066 demonstrated improved efficacy. The average dosage of L-dopa used in IPX066, after accounting for availability, was 22% higher than in Sinemet and Entacapone.

IPX066 demonstrated less "off" time (3.8 hours instead of 5.2 hours per day). IPX066 demonstrated higher "on" time without dyskinesia (11.4 hours instead of 10 hours per day). Other measures favoured IPX066. There were more adverse events when taking IPX066. The most common adverse events were dyskinesia, insomnia, and confusional state for IPX066, and falling for Sinemet and Entacapone.

Reference : Parkinsonism Related Disorders [2014] Aug 15 [Epub ahead of print] (F.Stocchi, A.Hsu, S.Khanna, A.Ellenbogen, A.Mahler, G.Liang, U.Dillmann, R.Rubens, S.Kell, S. Gupta)
Complete abstract  For more news go to Parkinson's Disease News

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.


PARKINSON'S DISEASE BOOKS from Amazon


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
©2006-2014  Viartis
 
2014-12-26 16:47:17
 
[email protected]